Decoy Therapeutics Inc. Income (Loss) from Continuing Operations, Per Diluted Share
Decoy Therapeutics Inc. (DCOY) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$4.46 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2026-08-12
- Decoy Therapeutics Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2026-06-30 was -$4.46.
- Decoy Therapeutics Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2026-03-31 was -$4.18.
- Decoy Therapeutics Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2025-06-30 was -$81.21.
- Decoy Therapeutics Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2025-03-31 was -$240.07.
- Decoy Therapeutics Inc. income (loss) from continuing operations, per diluted share for fiscal 2025 was -$129.10.
- Decoy Therapeutics Inc. income (loss) from continuing operations, per diluted share for fiscal 2024 was -$69.54.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|
| 2026-06-30 | -$4.46 10-Q · filed 2026-08-12 | -$8.64 10-Q · filed 2026-08-12 | |
| 2026-03-31 | -$4.18 10-Q · filed 2026-05-08 | ||
| 2025-12-31 | -$129.10 10-K · filed 2026-03-31 | ||
| 2025-06-30 | -$81.21 10-Q · filed 2026-08-12 | -$253.72 10-Q · filed 2026-08-12 | |
| 2025-03-31 | -$240.07 10-Q · filed 2026-05-08 | ||
| 2024-12-31 | -$69.54 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |